{"id":3725,"date":"2020-08-26T09:16:52","date_gmt":"2020-08-26T09:16:52","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/oxford-immunotec-releases-t-spot-discovery-sars-cov-2-kit-for-research-into-measuring-t-cell-immune-response-to-sars-cov-2\/"},"modified":"2021-01-08T11:20:31","modified_gmt":"2021-01-08T11:20:31","slug":"oxford-immunotec-releases-t-spot-discovery-sars-cov-2-kit-for-research-into-measuring-t-cell-immune-response-to-sars-cov-2","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/oxford-immunotec-releases-t-spot-discovery-sars-cov-2-kit-for-research-into-measuring-t-cell-immune-response-to-sars-cov-2\/","title":{"rendered":"Oxford Immunotec releases T-SPOT Discovery SARS-CoV-2 kit for research into measuring T cell immune response to SARS-CoV-2"},"content":{"rendered":"<p>Oxford Immunotec Global has released the T-SPOT Discovery SARS-CoV-2 test kit. The kit is for research use only and could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic.<br \/>\nT-SPOT Discovery SARS-CoV-2 builds on Oxford Immunotec\u2019s experience with TB diagnosis and the assessment of immune response to CMV in transplant patients, to apply the Company\u2019s established, proprietary T-SPOT technology to the fight against COVID-19.<br \/>\nWhile serology is able to detect antibodies to SARS-CoV-2 in the blood of some individuals after infection, little is known about how this confers immunity to COVID-19. T-SPOT technology goes further than simple serology by interrogating the immune system\u2019s T cell response and will enable research into the measurement of the strength of that response to SARS-CoV-2. The strength of this response may be linked to protection from reinfection.<br \/>\nCommenting on the technology, Phill Keefe, Senior Vice President Product Design, Development and Delivery at Oxford Immunotec, said: \u201cNot everyone with COVID-19 infection has detectable antibodies in serology tests, and this may be a bigger problem in the majority who experience only mild or no symptoms. Also, it is not yet clear whether the presence of anti-bodies confers immunity. T cell responses develop before antibody generation and can independently provide protection, so studying T cells could give us new insights into immunity to COVID-19.\u201d<br \/>\nT-SPOT technology is approved in over 60 countries for clinical use to detect TB infection. With over 20 million clinical tests since release, T-SPOT technology:<\/p>\n<ul>\n<li>Uses a standardized sample prepared from peripheral blood which:<br \/> &#8211; Reduces the influence of factors which might affect results, such as other treatments<br \/> &#8211; Standardises cell numbers in the test to normalise for cell number variations between samples<\/li>\n<li>Allows the number of responding T cells to be enumerated for a more precise assessment of the T cell response<\/li>\n<li>Is able to maintain performance, even in samples from immunosuppressed individuals<\/li>\n<li>Can be run in high-volume labs enabling large testing programs to be rolled out.<\/li>\n<\/ul>\n<p>T-SPOT technology can also be automated using the T-Cell Select reagent kit. Automation solutions are available for low, medium and high throughput settings.<br \/>\nFor more information, visit: <link http:\/\/go.oxfordimmunotec.com\/t-spot_discovery_SARS_CoV-2 _blank>go.oxfordimmunotec. com\/t-spot_discovery_SARS_CoV-2<\/link>\n<!--more--><br \/>\n<strong>Supplier:<\/strong> Immunotech Inc<br \/>\n<strong>Website:<\/strong> <a href=\"\" target=\"_blank\" rel=\"noopener noreferrer\"><\/a><\/p>\n<p><a class=\"avia-button avia-color-theme-color\" href=\"mailto:oxford_immunotec@3wmedia.nl\">Mail the supplier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oxford Immunotec Global has released the T-SPOT Discovery SARS-CoV-2 test kit. The kit is for research use only and could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic. T-SPOT Discovery SARS-CoV-2 builds on Oxford Immunotec\u2019s experience with TB diagnosis and the assessment of immune response to CMV in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":11200,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[36,39],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/3725"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=3725"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/3725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/11200"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=3725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=3725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=3725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}